Supplementary Materials

Supplementary Material for:

Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis

David Lagares,* Alba Santos, Paula E. Grasberger, Fei Liu, Clemens K. Probst, Rod A. Rahimi, Norihiko Sakai, Tobias Kuehl, Jeremy Ryan, Patrick Bhola, Joan Montero, Mohit Kapoor, Murray Baron, Xaralabos Varelas, Daniel J. Tschumperlin, Anthony Letai, Andrew M. Tager

*Corresponding author. Email: dlagares{at}mgh.harvard.edu

Published 13 December 2017, Sci. Transl. Med. 9, eaal3765 (2017)
DOI: 10.1126/scitranslmed.aal3765

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Effect of pan-caspase inhibitor Z-VAD and caspase-8 inhibitor emricasan on myofibroblast apoptosis induced by FAK inhibition.
  • Fig. S2. siRNA transfection efficiency and gene expression of BCL-2, BCL-XL, and MCL-1.
  • Fig. S3. Effect of YAP/TAZ knockdown and overexpression on fibroblastmitochondrial priming and survival.
  • Fig. S4. BH3 profiling of Normal 3, Scleroderma 4, and Scleroderma 6 fibroblasts.
  • Fig. S5. Effect of FAK and ROCK inhibition on mitochondrial priming and antiapoptotic BCL-2 members.
  • Fig. S6. Targeted apoptosis of myofibroblast reverses established fibrosis.
  • Table S1. Reverse transcription PCR primer and siRNA sequences.

[Download PDF]